

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
JOHN FEDER, ET AL.
APPLICATION NO: 10/761,905
FILED: 01/21/2004
FOR: POLYNUCLEOTIDE ENCODING A NOVEL ACYL COENZYME A,
MONOACYLGLYCEROL ACYLTRANSFERASE-3 (MGAT3), AND USES
THEREOF

ART UNIT: 1652
EXAMINER: SAIDHA, TEKCHAND
CONFIRMATION NO.: 4411

FILED VIA EFS-WEB

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


These references were cited in a Foreign Office Action in the corresponding European Application. Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,



Brian C. Carey
Attorney for Applicant
Reg. No. 44,590
Phone: 609-252-3883

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Date: April 12, 2007